The innovative high-resolution technology and integration of next-generation sequencing in cancer characterization have allowed for the identification of melanoma driver mutations and have led to the integration of alternative targeted therapies such as tyrosine kinase inhibitors in c-KIT relapsed and refractory melanomas. This evidence concerns the gene KIT and melanoma.